[go: up one dir, main page]

HK1162948A1 - 哈米特林 衍生物及其在治療癌症中的應用 - Google Patents

哈米特林 衍生物及其在治療癌症中的應用

Info

Publication number
HK1162948A1
HK1162948A1 HK12103605.7A HK12103605A HK1162948A1 HK 1162948 A1 HK1162948 A1 HK 1162948A1 HK 12103605 A HK12103605 A HK 12103605A HK 1162948 A1 HK1162948 A1 HK 1162948A1
Authority
HK
Hong Kong
Prior art keywords
hemiasterlin
cancer
treatment
derivatives
hemiasterlin derivatives
Prior art date
Application number
HK12103605.7A
Other languages
English (en)
Inventor
J Kowalczyk James
Kuznetsov Galina
Schiller Shawn
M Seletsky Boris
Spyvee Mark
Yang Hu
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of HK1162948A1 publication Critical patent/HK1162948A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK12103605.7A 2002-03-22 2012-04-12 哈米特林 衍生物及其在治療癌症中的應用 HK1162948A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36659202P 2002-03-22 2002-03-22

Publications (1)

Publication Number Publication Date
HK1162948A1 true HK1162948A1 (zh) 2012-09-07

Family

ID=28675269

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12103605.7A HK1162948A1 (zh) 2002-03-22 2012-04-12 哈米特林 衍生物及其在治療癌症中的應用

Country Status (19)

Country Link
US (5) US7192972B2 (zh)
EP (2) EP2374454B1 (zh)
JP (3) JP5042444B2 (zh)
KR (1) KR101208266B1 (zh)
CN (1) CN1633289A (zh)
AU (1) AU2003228354B8 (zh)
BR (1) BRPI0308606B8 (zh)
CA (1) CA2479764C (zh)
HK (1) HK1162948A1 (zh)
IL (2) IL163868A0 (zh)
MX (1) MXPA04009209A (zh)
NO (1) NO334803B1 (zh)
NZ (2) NZ535139A (zh)
PH (1) PH12013500123A1 (zh)
PL (1) PL219737B1 (zh)
RU (1) RU2342399C2 (zh)
TW (1) TWI332835B (zh)
WO (1) WO2003082268A2 (zh)
ZA (1) ZA200407611B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
PL219737B1 (pl) * 2002-03-22 2015-07-31 Eisai R & D Man Co Pochodne hemiasterliny, środek farmaceutyczny i zastosowanie pochodnych i zastosowanie hemiasterliny
US7390910B2 (en) * 2003-08-08 2008-06-24 Wyeth Compounds for treating tumors
US7317019B2 (en) 2003-08-21 2008-01-08 Bristol Myers Squibb Co. N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
WO2006063135A2 (en) * 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Tubulin isotype screnning in cancer therapy using hemiasterlin analogs
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
EA030611B1 (ru) 2013-03-15 2018-08-31 Кэнсер Рисерч Текнолоджи, Ллк Способы и композиции для модуляции гамма-глутамилового цикла
US10201614B2 (en) * 2013-03-15 2019-02-12 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
CA2935064C (en) 2013-12-27 2023-06-27 Zymeworks Inc. Var2csa-drug conjugates
EP3086815B1 (en) 2013-12-27 2022-02-09 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
JP6875273B2 (ja) 2014-09-17 2021-05-19 ザイムワークス インコーポレイティド 細胞傷害性及び抗有糸分裂性化合物、ならびにその使用方法
US10844090B2 (en) 2015-01-30 2020-11-24 Sutro Biopharma, Inc. Hemiasterlin derivatives for conjugation and therapy
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
WO2018128745A1 (en) 2017-01-06 2018-07-12 The Board Of Trustees Of The Leland Stanford Junior University Ciliary neurotrophic factor receptor ligands and methods of using the same
JP7202301B2 (ja) * 2017-08-10 2023-01-11 住友ファーマ株式会社 ヘミアスタリン誘導体及びこれらの抗体薬物複合体
FI3666787T3 (fi) 2017-08-10 2024-03-15 Sumitomo Pharma Co Ltd Hemiasterliinijohdannaisen sisältäviä vasta-aine-lääkekonjugaatteja
US12178879B2 (en) 2019-02-13 2024-12-31 Sumitomo Pharma Co., Ltd. Hemiasterlin derivative and antibody-drug conjugate thereof
US20220144889A1 (en) 2019-02-13 2022-05-12 Sumitomo Dainippon Pharma Co., Ltd. Hemiasterlin Derivative Having Cysteine Residue
WO2020166613A1 (ja) * 2019-02-13 2020-08-20 大日本住友製薬株式会社 多能性幹細胞の除去剤
EP4079327A1 (en) 2021-04-22 2022-10-26 Centaurus Polytherapeutics Payloads for drug-conjugates and their use for treating cancer
CN114195684B (zh) * 2021-12-21 2023-10-20 马鞍山诺恩特医药科技有限公司 一种氨基保护基n-取代手性氨基酸的合成方法
WO2025005765A1 (ko) * 2023-06-29 2025-01-02 주식회사 피노바이오 신규한 헤미아스텔린 유도체 및 이의 용도

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4768523A (en) 1981-04-29 1988-09-06 Lifecore Biomedical, Inc. Hydrogel adhesive
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5041126A (en) 1987-03-13 1991-08-20 Cook Incorporated Endovascular stent and delivery system
US5213580A (en) 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US5328471A (en) 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US5089606A (en) 1989-01-24 1992-02-18 Minnesota Mining And Manufacturing Company Water-insoluble polysaccharide hydrogel foam for medical applications
US5052998A (en) 1990-04-04 1991-10-01 Zimmon David S Indwelling stent and method of use
DE4016994A1 (de) * 1990-05-26 1991-11-28 Bayer Ag Neue anhydro-statin-phosphonopyrrolidine und -piperidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel gegen retroviren
US5064435A (en) 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
US5147370A (en) 1991-06-12 1992-09-15 Mcnamara Thomas O Nitinol stent for hollow body conduits
US5176626A (en) 1992-01-15 1993-01-05 Wilson-Cook Medical, Inc. Indwelling stent
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
JPH073444A (ja) * 1993-06-17 1995-01-06 Mitsubishi Materials Corp 耐割損性のすぐれた半導体装置の誘電薄膜形成用スパッタリング焼結ターゲット材
JPH0873444A (ja) 1994-09-02 1996-03-19 Fujisawa Pharmaceut Co Ltd ベンゾジアゼピン誘導体
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
EP0910572B1 (en) * 1996-05-14 2005-04-27 Agouron Pharmaceuticals, Inc. Inhibitors of picornavirus 3c proteases and methods for their use and preparation
US6057297A (en) * 1996-08-06 2000-05-02 Polifarma S.P.A. Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof
DE19638870B4 (de) 1996-09-23 2009-05-14 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysine, Verfahren zu ihrer Gewinnung und sie enthaltende Mittel
ZA9710342B (en) 1996-11-25 1998-06-10 Alza Corp Directional drug delivery stent and method of use.
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6143721A (en) 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US5891507A (en) 1997-07-28 1999-04-06 Iowa-India Investments Company Limited Process for coating a surface of a metallic stent
US5962487A (en) * 1997-12-16 1999-10-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
AU726917B2 (en) * 1997-12-19 2000-11-23 Upfield Europe B.V. Olive oil containing food composition
CA2225325A1 (en) * 1997-12-19 1999-06-19 The University Of British Columbia Hemiasterlin analogs
WO1999051613A1 (en) 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
HU227912B1 (en) 1998-06-17 2012-05-29 Eisai R & D Man Co Halichondrin analogs and methods of their use and preparation
WO1999065299A1 (en) * 1998-06-19 1999-12-23 Smithkline Beecham Corporation Compositions and methods for expansion of hematopoietic cells
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6248127B1 (en) 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
US7022677B1 (en) * 1999-02-18 2006-04-04 Kaken Pharmaceutical Co., Ltd. Amide derivatives as growth hormone secretagogues
KR100699404B1 (ko) * 1999-02-18 2007-03-23 가켄 세야쿠 가부시키가이샤 성장 호르몬 분비촉진제로서의 신규 아미드 유도체
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6323315B1 (en) * 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6203551B1 (en) 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
PA8515201A1 (es) 2000-04-14 2002-10-24 Agouron Pharma Compuestos y composiciones antipicornavirales; sus usos farmaceuticos y los materiales para su sintesis
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
US6517889B1 (en) 2001-11-26 2003-02-11 Swaminathan Jayaraman Process for coating a surface of a stent
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
PL219737B1 (pl) 2002-03-22 2015-07-31 Eisai R & D Man Co Pochodne hemiasterliny, środek farmaceutyczny i zastosowanie pochodnych i zastosowanie hemiasterliny
DE10230874A1 (de) 2002-07-09 2004-01-22 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Tubulysinanaloga
AU2003294463A1 (en) 2002-11-21 2004-06-18 Wyeth Cells resistant to chemotherapeutic compounds and uses thereof
WO2004047615A2 (en) 2002-11-21 2004-06-10 Wyeth Hemiasterlin affinity probes and their uses
WO2006063135A2 (en) 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Tubulin isotype screnning in cancer therapy using hemiasterlin analogs
KR20080006012A (ko) 2005-05-05 2008-01-15 에자이 가부시키가이샤 (2ｅ,4ｓ)-4-[(ｎ-｛[(2ｒ)-1-이소프로필피페리딘-2-일]-카르보닐｝-3-메틸-ｌ-발릴)(메틸)아미노]-2,5-디메틸헥스-2-엔산의 비용매화된 결정성 형태 및 호스트-게스트 용매화된결정성 형태, 및 그의 약제학적 용도

Also Published As

Publication number Publication date
EP1490054A2 (en) 2004-12-29
PL219737B1 (pl) 2015-07-31
NZ535139A (en) 2007-07-27
JP2013166754A (ja) 2013-08-29
TWI332835B (en) 2010-11-11
US20140309174A1 (en) 2014-10-16
NO334803B1 (no) 2014-05-26
TW200407122A (en) 2004-05-16
US8633224B2 (en) 2014-01-21
JP2007332160A (ja) 2007-12-27
BRPI0308606B8 (pt) 2021-05-25
JP5042444B2 (ja) 2012-10-03
US8129407B2 (en) 2012-03-06
EP2374454A1 (en) 2011-10-12
US20050239870A1 (en) 2005-10-27
US7528152B2 (en) 2009-05-05
KR101208266B1 (ko) 2012-12-05
NZ555951A (en) 2009-01-31
AU2003228354B2 (en) 2010-02-11
NO20044526L (no) 2004-12-21
BR0308606A (pt) 2005-04-26
IL163868A0 (en) 2005-12-18
CA2479764A1 (en) 2003-10-09
KR20040091748A (ko) 2004-10-28
AU2003228354A1 (en) 2003-10-13
CA2479764C (en) 2013-07-30
CN1633289A (zh) 2005-06-29
AU2003228354B8 (en) 2010-03-04
EP2374454B1 (en) 2016-05-11
US20120309938A1 (en) 2012-12-06
JP2005530717A (ja) 2005-10-13
WO2003082268A3 (en) 2004-09-23
WO2003082268A2 (en) 2003-10-09
ZA200407611B (en) 2008-02-27
US20080051434A1 (en) 2008-02-28
US20100063095A1 (en) 2010-03-11
RU2004131218A (ru) 2005-05-27
BRPI0308606B1 (pt) 2019-01-15
PL373572A1 (en) 2005-09-05
MXPA04009209A (es) 2004-11-26
PH12013500123A1 (en) 2015-10-26
US7192972B2 (en) 2007-03-20
RU2342399C2 (ru) 2008-12-27
IL163868A (en) 2011-11-30

Similar Documents

Publication Publication Date Title
HK1162948A1 (zh) 哈米特林 衍生物及其在治療癌症中的應用
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
HK1089155A1 (en) Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
AU2003284242A1 (en) Methods and compositions for use in treating cancer
IL174479A0 (en) Hemiasterlin derivatives and uses thereof
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
AU2003212634A8 (en) Compounds useful in the treatment of cancer
AU2003274963A1 (en) Mda-7 and free radicals in the treatment of cancer
PL368035A1 (en) Compositions and methods for the treatment of cancer
IL162941A0 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
EP1551452A4 (en) COMPOSITIONS AND METHODS FOR THERAPEUTIC TREATMENT
EP1583543A4 (en) METHOD AND THERAPEUTIC COMPOSITIONS IN THE TREATMENT OF ADVANCED CARCINOMA
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU2002346049A1 (en) Coactivators in the diagnosis and treatment of breast cancer
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
AU2003244437A1 (en) Quinoxalinones and their use especially in the treatment of cardiovascular diseases
AU2003247094A8 (en) Enhancing the effect of radioimmunotherapy in the treatment of tumors
AU2003268463A8 (en) Asialo-interferons and the treatment of liver cancer
AU2003301167A8 (en) Breast specific protein expressed in cancer and methods of use thereof
AU2003251763A1 (en) Interferon gamma in the detection and treatment of angiomyolipomas
AU2003246880A8 (en) Alkaloid-derived compounds and use thereof in cancer and malaria treatment

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230318